Nat. Rev. Cardiol. doi: /nrcardio

Slides:

Advertisements

Similar presentations

Inhibitory Effects of Ticagrelor Compared to Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes The PLATO PLATELET Substudy Storey.

Advertisements

Prasugrel vs ticagrelor in acute coronary syndromes

High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function and Inflammation.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Patients With Poor Responsiveness to Thienopyridine.

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pharmacodynamic Effects of Switching From Prasugrel.

Challenges with Drug Administration Optimal Loading Dose and Delivery of P2Y12 Inhibitors: Should the Loading Dose Be Crushed? Dominick J. Angiolillo,

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Crushed Prasugrel Tablets in Patients With STEMI.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impaired Responsiveness to the Platelet P2Y 12 Receptor.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel.

Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI

When to Switch and How to Switch

Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.

Women, Bleeding, and Coronary Intervention

Nat. Rev. Cardiol. doi: /nrcardio

Francesco Franchi, MD, Fabiana Rollini, MD, Jose Rivas Rios, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Megha Kureti, MD, Deepa Nagaraju, MD, Mustafa Wali,

Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype status. Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype.

Glenn N. Levine et al. JACC 2016;68:

Figure 3 Metabolism pathway of antiplatelet agents

Figure 2 Binding properties of P2Y12-receptor inhibitors

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Pharmacodynamic comparison of crushed versus integral

Figure 4 BMI and mortality in patients with heart failure

Figure 1 Energy supply–demand matching in health and heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Anatomy of the femoral artery

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Three-year survival rates on the basis of body composition

Nat. Rev. Cardiol. doi: /nrcardio

Figure 8 4D magnetic resonance imaging patterns

Nat. Rev. Cardiol. doi: /nrcardio

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile.

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Figure 2 Imaging of atherosclerotic plaque burden

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Becker RC, et al. Lancet 2009;373:919-28

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Figure 1 PCI strategies in patients with STEMI and multivessel disease

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Observational studies on multiple treatment strategies

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 The neurogenic components of angina

Nat. Rev. Cardiol. doi: /nrcardio

Figure 9 Management of atrial fibrillation

Figure 1 Platelet receptors and available pharmaceutical options

International Journal of Cardiology

Cardiology Fellow X Factor: An ACS Case of Therapeutic Challenges

Figure 2 Impaired mitochondrial capacity and function in heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Roberta Rossini et al. JCIN 2018;11:

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2015.113 Figure 4 Pharmacodynamic profile of switching from clopidogrel to prasugrel therapy: the TRIPLET study Figure 4| Pharmacodynamic profile of switching from clopidogrel to prasugrel therapy: the TRIPLET study.47 Time course of platelet inhibition measured as a | P2Y12 reaction units, and b | percent of inhibition, in patients with an acute coronary syndrome whose therapy was switched from clopidogrel to prasugrel. Eligible patients undergoing a percutaneous coronary intervention were randomly assigned to receive one of three therapeutic strategies. The results at time 0 are the baseline values obtained after intake of the first clopidogrel or placebo LDs, immediately before the second LD (with prasugrel) was administered. *No significant difference. **P <0.05. Data are presented as the least squares mean ± SE. Abbreviations: LD, loading dose; MD, maintenance dose. Reprinted from Diodati, J. G. et al. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial. Circ. Cardiovasc. Interv. 6 (5), 567–574 (2013), with permission from Wolters Kluwer Health and the American Heart Association. Reprinted from Diodati, J. G. et al. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial. Circ. Cardiovasc. Interv. 6 (5), 567–574 (2013), with permission from Wolters Kluwer Health and the American Heart Association Rollini, F. et al. (2015) Switching P2Y12-receptor inhibitors in patients with coronary artery disease Nat. Rev. Cardiol. doi:10.1038/nrcardio.2015.113